Profile | OTHERS

Hi we’re SPRIN-D!

SPRIN-D is Germany’s federal agency funding high-risk, high-reward synthetic biology projects focused on sustainable biomanufacturing and circular bioeconomy solutions. It supports innovation through grants and challenges that accelerate the development of breakthrough bioprocessing technologies.

Hi we’re LongeVC!

LongeVC is a venture capital firm focused on advancing an ageless future by investing in early-stage biotech and longevity companies developing breakthrough therapeutics and scalable bio-based material solutions.

Hi we’re IQ Capital!

Hi we’re 2ndF!

2ndF, a Venture Capital and Private Equity firm, invested in AI-powered cell manufacturing platform that leverages predictive modeling and high-throughput control to engineer human cells and organoids

Hi we’re Cape Fear BioCapital!

Founded in 2024, Cape Fear BioCapital is a North Carolina–based venture fund supporting emerging biotech companies, with investments including an AI-powered cell manufacturing platform that applies predictive modeling and high-throughput control to engineer human cells and organoids for drug discovery, regenerative medicine, and cell therapy.

Hi we’re First Star Ventures!

First Star Ventures invests in entrepreneurs applying frontier technologies like AI and computational biotech to solve real-world problems, including an AI-powered cell manufacturing platform that uses predictive modeling and high-throughput control to engineer human cells and organoids for drug discovery, regenerative medicine, and cell therapy.

Hi we’re KNIH!

The Korea National Institute of Health, a leading medical research institution supporting public health and health policy in South Korea took part in national initiative to to sequence over 1,000 Korean genomes using high-quality sequencing technologies, establishing global reference standards to advance disease research and precision medicine.

Hi we’re KDCA!

The Korea Disease Control and Prevention Agency (KDCA) leads the Korean Pangenome Reference Project, a national initiative to sequence over 1,000 Korean genomes using high-quality sequencing technologies, establishing global reference standards to advance disease research and precision medicine.